HC Wainwright Issues Positive Forecast for VYGR Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Investment analysts at HC Wainwright upped their Q1 2025 earnings per share (EPS) estimates for shares of Voyager Therapeutics in a research note issued on Thursday, March 13th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.21) for the quarter, up from their previous forecast of ($0.30). HC Wainwright has a "Buy" rating and a $30.00 price objective on the stock. The consensus estimate for Voyager Therapeutics' current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Voyager Therapeutics' Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.86) EPS, FY2026 earnings at ($1.04) EPS, FY2027 earnings at ($1.07) EPS, FY2028 earnings at ($1.47) EPS and FY2029 earnings at ($1.40) EPS.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The firm had revenue of $4.39 million for the quarter, compared to analysts' expectations of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter in the prior year, the business earned $1.25 EPS.

A number of other brokerages have also recently commented on VYGR. Canaccord Genuity Group dropped their target price on Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, March 13th. Wells Fargo & Company set a $10.00 target price on Voyager Therapeutics and gave the stock an "overweight" rating in a report on Wednesday, March 12th. StockNews.com cut Voyager Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, December 13th. Citigroup began coverage on Voyager Therapeutics in a report on Monday, December 2nd. They issued a "buy" rating and a $12.00 target price for the company. Finally, Wedbush reiterated an "outperform" rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. One analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Voyager Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $14.86.

Remove Ads

Voyager Therapeutics Stock Down 6.2 %

NASDAQ VYGR traded down $0.26 during trading on Monday, hitting $3.84. 160,405 shares of the stock traded hands, compared to its average volume of 472,289. The company has a market capitalization of $211.72 million, a P/E ratio of 5.42 and a beta of 0.99. The firm has a 50-day simple moving average of $4.72 and a 200-day simple moving average of $5.77. Voyager Therapeutics has a 12-month low of $3.56 and a 12-month high of $10.66.

Institutional Investors Weigh In On Voyager Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC raised its position in Voyager Therapeutics by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company's stock valued at $6,316,000 after purchasing an additional 6,740 shares in the last quarter. FMR LLC raised its position in Voyager Therapeutics by 26.9% during the 3rd quarter. FMR LLC now owns 92,498 shares of the company's stock valued at $541,000 after purchasing an additional 19,622 shares in the last quarter. Barclays PLC raised its position in Voyager Therapeutics by 55.8% during the 3rd quarter. Barclays PLC now owns 104,462 shares of the company's stock valued at $612,000 after purchasing an additional 37,398 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in Voyager Therapeutics by 23.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company's stock valued at $223,000 after purchasing an additional 7,573 shares in the last quarter. Finally, Rhumbline Advisers raised its position in Voyager Therapeutics by 3.4% during the 4th quarter. Rhumbline Advisers now owns 71,497 shares of the company's stock valued at $405,000 after purchasing an additional 2,354 shares in the last quarter. 48.03% of the stock is owned by institutional investors.

Insider Activity at Voyager Therapeutics

In related news, COO Robin Swartz sold 6,500 shares of the business's stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the transaction, the chief operating officer now owns 112,328 shares in the company, valued at $634,653.20. The trade was a 5.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 10,778 shares of company stock worth $58,548 in the last quarter. 4.53% of the stock is owned by company insiders.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.